Award Winning Validation HemoSonics has earned multiple prestigious awards including the 2026 Edison Silver Award for its Quantra Hemostasis System, as well as recognition in 2024 and 2025 accolades. This demonstrates proven market credibility and strong third-party validation that can be leveraged when engaging with hospital procurement and surgeons.

Maternal Health Focus Public statements highlight a commitment to reducing maternal mortality from severe bleeding, with specific recognition in the Women’s Health category. This positions the Quantra system as a strategic fit for obstetric departments and maternity centers seeking advanced point-of-care coagulation management.

Point-of-Care Advantage The Quantra system is cartridge-based, rapid, and designed for perioperative coagulation assessment at the point of care. This aligns with operating rooms and emergency settings seeking faster decision-making tools, suggesting sales opportunities in perioperative suites and trauma clinics.

Growth and Scale Signals With revenue in the mid tens of millions and an active investor-friendly funding footprint plus a growing customer base, HemoSonics is expanding its reach in the medical device market. Opportunities exist to partner with distributors, hospital networks, and large integrated delivery networks (IDNs) looking to standardize viscoelastic testing.

Strategic Partnerships Recent accolades from Premier, Fast Company, TIME Best Inventions and other industry awards indicate strong market momentum. This momentum can be leveraged to pursue co-marketing with clinical stakeholders, supply chain collaborations, and joint education programs to accelerate adoption of the Quantra system.